HER2-positive advanced breast cancer

被引：5

作者：

Robert, Nicholas J. ^{[1
]}

Favret, Anne M. ^{[1
]}

机构：

[1] US Oncol Res Network, Fairfax No Virginia Hematol Oncol, Fairfax, VA 22031 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2007年 / 21卷 / 02期

关键词：

D O I：

10.1016/j.hoc.2007.03.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It is important when treating a patient who has advanced breast cancer to establish the biologic characteristics of the tumor. In addition to knowing the hormone receptor status (estrogen and progesterone), human epidermal receptor 2 (HER2) should be evaluated. The measurement of this parameter is essential to optimizing the systemic management. This article reviews the biology of HER2, testing for HER2, clinical studies evaluating HER2-based therapies, side effects (specifically cardiotoxicity), and strategies for HER2-based therapies.

引用

页码：293 / +

页数：12

共 51 条

[1] Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
Bartsch, R
Wenzel, C
Hussian, D
Pluschnig, U
Sevelda, U
Koestler, W
Altorjai, G
Locker, GJ
Mader, R
Zielinski, CC
Steger, GG
[J]. BMC CANCER, 2006, 6 (1)
[2] Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
Baselga, J
Carbonell, X
Castañeda-Soto, NJ
Clemens, M
Green, M
Harvey, V
Morales, S
Barton, C
Ghahramani, P
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2162 - 2171
[3] Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
Bendell, JC
Domchek, SM
Burstein, HJ
Harris, L
Younger, J
Kuter, I
Bunnell, C
Rue, M
Gelman, R
Winer, E
[J]. CANCER, 2003, 97 (12) : 2972 - 2977
[4] Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer
Burris, H
Yardley, D
Jones, S
Houston, G
Broome, C
Thompson, D
Greco, FA
White, M
Hainsworth, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1621 - 1629
[5] BURSTEIN H, 2006, J CLIN ONCOL, V24, P185
[6] Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
Burstein, HJ
Harris, LN
Marcom, PK
Lambert-Falls, R
Havlin, K
Overmoyer, B
Friedlander, RJ
Gargiulo, J
Strenger, R
Vogel, CL
Ryan, PD
Ellis, MJ
Nunes, RA
Bunnell, CA
Campos, SM
Hallor, M
Gelman, R
Winer, EP
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2889 - 2895
[7] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
Burstein, HJ
Kuter, I
Campos, SM
Gelman, RS
Tribou, L
Parker, LM
Manola, J
Younger, J
Matulonis, U
Bunnell, CA
Partridge, AH
Richardson, PG
Clarke, K
Shulman, LN
Winer, EP
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2722 - 2730
[8] Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial
Chia, Stephen
Clemons, Mark
Martin, Lee-Ann
Rodgers, Angela
Gelmon, Karen
Pond, Gregory R.
Panasci, Lawrence
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2773 - 2778
[9] CHIEN K, 2006, NEW ENGL J MED, V354, P809
[10] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
Cobleigh, MA
Vogel, CL
Tripathy, D
Robert, NJ
Scholl, S
Fehrenbacher, L
Wolter, JM
Paton, V
Shak, S
Lieberman, G
Slamon, DJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2639 - 2648

← 1 2 3 4 5 6 →